Skip to main content

Aliquots Archives

Pushing (anti-overdose) drugs

May. 23, 2022—An automated alert to encourage clinicians to coprescribe naloxone for patients at risk of opioid overdose increased naloxone prescriptions per opioid prescription 16-fold.

Read more


Genetics and blood pressure

May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

Read more


A clue to an adverse drug event in children

May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Read more


Autism and sleep problems

May. 10, 2022—Vanderbilt researchers developed a framework for using de-identified medical records to characterize sleep in people on the autism spectrum — a framework that should also be useful for studying other neurodevelopmental disorders.

Read more


Gene variants and transplant drug dose

May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

Read more


COVID-associated bleeding risk

May. 5, 2022—While case reports have noted acquired hemophilia after COVID-19 infection or vaccination, a new study finds no increased risk.

Read more


Gene network linked to Type 2 diabetes

May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

Read more


Calculating risk for uterine fibroids

Apr. 26, 2022—Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Read more


Molecular testing across tumor types

Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Read more


When science spills onto social media

Apr. 21, 2022—Vanderbilt researchers report that social media posts can offer insights into how the public feels about genome editing, with stances varying across platforms and differing from those of academics and policy makers.

Read more


Youthful healing for burn wounds

Apr. 21, 2022—Topical treatment of burns with an immunosuppressive drug counteracted the negative effects of aging on wound healing, Vanderbilt researchers have discovered.

Read more


Financial impact of prior authorization

Apr. 12, 2022—Prior authorization — health insurer approval of a medical intervention prior to treatment — costs more than $40 million for U.S. academic radiation oncology practices, with questionable value added to patient care.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more